Proxy Votes Now

Home › Funds › VanEck ETF Trust › VanEck Biotech ETF

VanEck Biotech ETF (BBH) proxy voting record 2025-2026

Fund family: VanEck ETF Trust · Filed by VanEck ETF Trust (CIK 1137360) · SEC series S000034406

Ticker: BBH (C000105864)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 299 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 2 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with VanEck ETF Trust as a whole

The same two figures as VanEck ETF Trust’s manager page (28,640 ballot items across 55 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsVanEck ETF TrustItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.8%27789.2%21,516
Backed environmental and social shareholder proposals at US companiesn/a116.2%309

Where this fund voted differently from most VanEck ETF Trust funds

Each ballot item this fund voted is set against the votes of the other VanEck ETF Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most VanEck ETF Trust funds on all 13 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 68.5% of this fund’s 305 such votes could be given a sector; the other 96 (31.5%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care19963.0%
Technology1000.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1880
Audit-related270
Corporate Governance253
Say-on-Pay240
Compensation211
Capital Structure190
Extraordinary Transactions20
Other Social Issues11
Shareholder Rights and Defenses11

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Amgen Inc.May 19, 2026$80M151
Gilead Sciences, Inc.April 30, 2026$74M153
Moderna, Inc.November 12, 2025$53M20
Vertex Pharmaceuticals IncorporatedMay 13, 2026$41M151
Regeneron Pharmaceuticals, Inc.June 12, 2026$34M70
argenx SEMay 6, 2026$26M120
Natera, Inc.June 11, 2026$21M80
argenx SENovember 18, 2025$21M10

Notable votes against management

MeetingCompanyProposalFundMgmt
May 19, 2026Amgen Inc.Stockholder proposal to require an independent board chairman. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposalForAgainst
April 30, 2026Gilead Sciences, Inc.To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposalAgainstFor
May 13, 2026Vertex Pharmaceuticals IncorporatedShareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposalForAgainst
April 23, 2026IQVIA Holdings Inc.If properly presented, a stockholder proposal concerning separate Chairman and Chief Executive Officer roles. Shareholder proposalForAgainst

Search this fund’s votes by company

308 ballot items at 28 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, VanEck Biotech ETF (BBH) voted at 28 shareholder meetings of 26 companies, on 308 ballot items in all. Where management made a recommendation, the fund followed it on 98.0% of the items and voted against it 6 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals more often than VanEck ETF Trust's funds as a whole (92.8% against 89.2%). It voted the same way as most VanEck ETF Trust funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of VanEck ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.